HIV Receives a “One Two Knockout Punch”

Slides:



Advertisements
Similar presentations
Volume 20, Issue 2, (February 2012)
Advertisements

Man's Best Friend: Utilizing Naturally Occurring Tumors in Dogs to Improve Chimeric Antigen Receptor T-cell Therapy for Human Cancers  Melinda Mata, Stephen.
Engineering Natural Killer Cells for Cancer Immunotherapy
Genome-editing Technologies for Gene and Cell Therapy
627. Non-Invasive, Multimodal Imaging of Microvesicles with Metabolically Biotinylated, Membrane-Bound Gaussia Luciferase    Molecular Therapy  Volume.
Will Engineered T Cells Expressing CD20 scFv Eradicate Melanoma?
162. Stability of Polymer/Plasmid DNA Complexes In Vitro and In Vivo
281. Rapid Generation of Induced Pluripotent Stem Cells (iPSCs) from the Urine of a Patient with Duchenne Muscular Dystrophy    Molecular Therapy  Volume.
Molecular Therapy  Volume 20, Pages S261-S262 (May 2012) DOI: /S (16)
Evolving Gene Therapy in Primary Immunodeficiency
Volume 20, Issue 6, Pages (June 2012)
343. Benchtop DNA Synthesizer: Oligo-Templated Polymerization (OTP)
Engineering Natural Killer Cells for Cancer Immunotherapy
Escaping the Valley of Death
Donald B. Kohn, MD, Caroline Y. Kuo, MD 
Volume 26, Issue 2, Pages (February 2018)
MicroRNAs: Panacea or Pandora's box?
Volume 25, Issue 1, Pages 5-7 (January 2017)
Xiuyan Wang, Isabelle Rivière  Molecular Therapy - Oncolytics 
Molecular Therapy - Nucleic Acids
Volume 25, Issue 5, Pages (May 2017)
CRISPR-Cas9 for in vivo Gene Therapy: Promise and Hurdles
CRISPR genome-editing: A medical revolution
The Other Face of Chimeric Antigen Receptors
724. Blood-Derived Endothelial Progenitor Cells Can Be Isolated With a Novel Method of Diluted Whole Blood Incubation with AMD3100-Induced Mobilization.
Current Progress in Therapeutic Gene Editing for Monogenic Diseases
Genome-editing Technologies for Gene and Cell Therapy
Valder R Arruda, Patricia Favaro, Jonathan D Finn  Molecular Therapy 
Harnessing regulatory T cells for therapeutic purposes
Premal Lulla, Carlos A. Ramos  Molecular Therapy 
Molecular Therapy  Volume 20, (May 2012) DOI: /S (16)
Molecular Therapy  Volume 7, Issue 5, (May 2003) DOI: /S (16)
847. Eradication of Therapy-Resistant Human Prostate Tumors Using an Ultrasound Guided Site-Specific Cancer Terminator Virus Delivery Approach    Molecular.
Designer Lipids Advance Systemic siRNA Delivery
Volume 25, Issue 5, Pages (May 2017)
Volume 20, Issue 6, Pages (June 2012)
Donna M. Martin, Yehoash Raphael  Molecular Therapy 
133. Survival with Normal Neurological Development of the Juvenile Lethal Urea Cycle Defect Arginase Deficient Mouse with AAV Gene Therapy    Molecular.
660. Bowel/Bladder Sensation and Control in Patients with Spinal Cord Injury Treated with Human Embryonic Stem Cell Therapy  Geeta Shroff  Molecular Therapy 
Volume 26, Issue 2, Pages (February 2018)
Volume 20, Issue 8, Pages (August 2012)
68. Site Specific Intra-Placental Gene Transfer Corrects Fetal Growth Restriction in a Novel Mouse Model of Placental Insufficiency (PI)    Molecular.
521. Multiplex Genome Editing of TCR°/CD52 Genes as a Platform for “Off the Shelf” Adoptive T-Cell Immunotherapies    Molecular Therapy  Volume 22, Pages.
A CRISPR Approach to Gene Targeting
Engineering HIV-Resistant, Anti-HIV Chimeric Antigen Receptor T Cells
405. Hindlimb and Forelimb Strength Assessment in a Canine Model of X-Linked Myotubular Myopathy Following AAV-Mediated Gene Replacement    Molecular.
Volume 26, Issue 4, Pages (April 2018)
674. Molecular, Biochemical and Biomechanical Analysis of Articular Cartilage Repaired with Genetically Modified Chondrocytes Expressing Insulin-Like.
The Cell Biology of Genomes: Bringing the Double Helix to Life
Chimeric antigen receptor T-cell therapy for solid tumors
Molecular Therapy  Volume 18, Pages S260-S261 (May 2010) DOI: /S (16)
In This Issue Molecular Therapy Volume 16, Issue 4, (April 2008)
Management of Cytokine Release Syndrome (CRS) in Patients Undergoing Chimeric Antigen Receptor Modified (CAR) T-Cell Therapy Following Autologous Stem.
Chimeric Antigen Receptor–Modified T Cells: Clinical Translation in Stem Cell Transplantation and Beyond  Stanley R. Riddell, Michael C. Jensen, Carl.
521. AAV Immunotherapy Induces Functional Antigen Specific Regulatory T-Cells to a Neuroantigen: A Potential Treatment for MS  Brad E. Hoffman  Molecular.
773. Detection of RNA Interference (RNAi) Mediated mRNA Cleavage in Fresh Injected Tumor Tissue from Patients in a Phase I Trial of pbi-shRNA™ Lipoplex.
740. Prevention of Radiation-Induced Lung Injury by Administration of Gene-Modified Mesenchymal Stem Cells    Molecular Therapy  Volume 20, Pages S285-S286.
Molecular Therapy  Volume 21, Pages S247-S248 (May 2013)
Natalay Kouprina, Vladimir Larionov 
Shigeki Yagyu, Malcolm K. Brenner
History of Oncolytic Viruses: Genesis to Genetic Engineering
86. A Highly Compact Epitope-Based Marker Suicide Gene for Safer and Easier Adoptive T-Cell Gene Therapy    Molecular Therapy  Volume 20, Pages S35-S36.
297. Minimally Invasive Implantation of Autologous Chondrocytes Transduced with rAAV5-IGF-I Improves Longterm Cartilage Repair in Full-Thickness Chondral.
Nuclease Target Site Selection for Maximizing On-target Activity and Minimizing Off- target Effects in Genome Editing  Ciaran M Lee, Thomas J Cradick,
CRISPR in Parasitology: Not Exactly Cut and Dried!
Thomas Gaj, Benjamin E Epstein, David V Schaffer  Molecular Therapy 
Volume 26, Issue 6, Pages (June 2018)
New Tools for Genome Modification in Human Embryonic Stem Cells
Sensing Bad: Are Co-stimulatory CAR-Expressing γδ T Cells Safer?
624. Randomized Phase II Trial of Adjuvant Autologous Tumor Cell Vaccine (FANG™) for High Risk Stage III/IV Ovarian Cancer: Preliminary Results    Molecular.
Presentation transcript:

HIV Receives a “One Two Knockout Punch” Conrad Russell Cruz, Catherine M. Bollard  Molecular Therapy  Volume 25, Issue 3, Pages 566-567 (March 2017) DOI: 10.1016/j.ymthe.2017.02.001 Copyright © 2017 The American Society of Gene and Cell Therapy Terms and Conditions

Figure 1 Harnessing Homology-Directed Repair for Gene Modification Homology-directed repair (HDR), represented here, (1) employs double strand breaks introduced by the megaTAL (blue triangle) in the region of interest (i.e., CCR5) and initiates repair via the (2) homologous regions (rounded red and green rectangles) present in a donor template to (3) switch in a transgene of interest (i.e., the chimeric antigen receptor targeting HIV [HIV CAR]) during the repair process. The use of HDR to introduce constructs has the advantages of simultaneously removing a gene while introducing a new one and of directed integration (avoiding potentially “unsafe” regions). Molecular Therapy 2017 25, 566-567DOI: (10.1016/j.ymthe.2017.02.001) Copyright © 2017 The American Society of Gene and Cell Therapy Terms and Conditions